Blood product administration during high risk neuroblastoma therapy-Reference-Cited by-同舟云学术

Blood product administration during high risk neuroblastoma therapy

Published:2019-12-12 Issue:1 Volume:37 Page:5-14
ISSN:0888-0018
Container-title:Pediatric Hematology and Oncology
language:en
Short-container-title:Pediatric Hematology and Oncology

Author:

Silverstein Allison¹^ORCID,Reddy Kiranmye²^ORCID,Smith Valeria²,Foster Jennifer H.²^ORCID,Russell Heidi V.²³,Whittle Sarah B.²^ORCID

Affiliation:

1. Department of Pediatrics, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas, USA;

2. Department of Pediatrics, Section of Hematology-Oncology, Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas, USA;

3. Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA

Publisher

Informa UK Limited

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/08880018.2019.1668095

Reference32 articles.

1. Insurance Status and the Use of Guideline Therapy in the Treatment of Selected Cancers

2. Infant Cancer in the U.S.

3. Kufe DW, Pollock RE, Weichselbaum R, et al. Holland-Frei Cancer Medicine. Ontario, Canada: BC Decker; 2003.

4. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

5. Advances in Risk Classification and Treatment Strategies for Neuroblastoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of patient factors associated with the number of transfusions required during chemotherapy for high‐risk neuroblastoma;Vox Sanguinis;2021-07